Remap Consulting

Has it been a week already? 🌎 At this year's World Orphan Drug Congress Europe, our team saw first-hand how the industry is bracing for key changes and innovations that will define 2025 and beyond. From navigating the EU HTA rollout to harnessing real-world data and amplifying patient voices, the congress highlighted essential strategies for the evolving rare disease landscape.   Catch our latest report for key insights:   🔹 Strategic insights from our panel on “Evidence Generation for Multiple Stakeholder Needs” 🔹 Perspectives on industry readiness for EU HTA implementation 🔹 Key takeaways from all the keynotes 🔹 New research on early access frameworks and specialised tech from our team at Remap   Curious about the latest in rare disease access? Click to read our report! 📖 🔗 https://lnkd.in/e4zQcdic   What was your #WODC2024 highlight? Share your thoughts in the comments!   #marketaccess #EUHTA #raredisease #orphandrugs #pharmaceuticals #healthcare #patientaccess

We’d like to extend a heartfelt thanks to our #WODC panellists - Dr. Ruth Pulikottil Jacob, Andrew Olaye, Daniel de Vicente and Josie Godfrey for their invaluable insights and for taking the time to share their perspectives on the unique challenges of evidence generation in rare diseases. “𝘉𝘳𝘪𝘯𝘨𝘪𝘯𝘨 𝘵𝘰𝘨𝘦𝘵𝘩𝘦𝘳 𝘴𝘶𝘤𝘩 𝘱𝘢𝘴𝘴𝘪𝘰𝘯𝘢𝘵𝘦 𝘷𝘰𝘪𝘤𝘦𝘴 𝘳𝘦𝘮𝘪𝘯𝘥𝘴 𝘶𝘴 𝘸𝘩𝘺 𝘱𝘢𝘵𝘪𝘦𝘯𝘵-𝘤𝘦𝘯𝘵𝘦𝘳𝘦𝘥 𝘢𝘱𝘱𝘳𝘰𝘢𝘤𝘩𝘦𝘴 𝘪𝘯 𝘳𝘢𝘳𝘦 𝘥𝘪𝘴𝘦𝘢𝘴𝘦𝘴 𝘢𝘳𝘦 𝘦𝘴𝘴𝘦𝘯𝘵𝘪𝘢𝘭," said Practice Lead Mariam Bibi, reflecting on the lively discussion. 🎥 Pop the sound on and watch the snippet below, where Josie discusses her experience across diverse global regions, emphasising how crucial cultural sensitivity is in patient engagement. From the UK to Russia, Singapore, and beyond, she explores alternative ways to ensure patient voices are heard; especially where direct advocacy is challenging. By collaborating with clinical communities and local groups, she illustrates how we can capture what matters most to patients, even when engagement takes a different path. 📄 For a deeper dive into the full panel discussion, check out our comprehensive session notes here ➡ https://lnkd.in/ecnGQDqE #MarketAccess #PatientAccess #Pharma #RareDiseases #PatientsFirst #EvidenceGeneration #HealthcareInnovation #WODC

🔍 𝐇𝐨𝐰 𝐜𝐚𝐧 𝐀𝐓𝐌𝐏𝐬 𝐩𝐫𝐨𝐯𝐞 𝐭𝐡𝐞𝐢𝐫 𝐞𝐜𝐨𝐧𝐨𝐦𝐢𝐜 𝐯𝐚𝐥𝐮𝐞 𝐭𝐨 𝐩𝐚𝐲𝐞𝐫𝐬? With the rapid rise of advanced therapy medicinal products (ATMPs), demonstrating a compelling economic case has never been more crucial. Our third piece of research for this year's conference dives into strategies for ATMPs to showcase their value effectively, featuring real-world insights that payers need today. At #ISPOREurope 2024, Paul Craddy will host a discussion hour, where you can explore these findings and discuss their implications for future market access. 📅 Join us on Tuesday 𝟏𝟗𝐭𝐡 𝐍𝐨𝐯𝐞𝐦𝐛𝐞𝐫, from 𝟏𝟐:𝟑𝟎 𝐭𝐨 𝟏:𝟑𝟎 𝐩𝐦 for this essential session that bridges innovation and access. Read the abstract here 👉 https://lnkd.in/e2kE9uvm #MarketAccess #HEOR #ATMPs #RealWorldEvidence #Pharma #Healthcare ISPOR—The Professional Society for Health Economics and Outcomes Research

That's a wrap on the World Orphan Drug Congress Europe 2024! 🏁 With the stand packed away and our team on their way home, we’re reflecting on an inspiring week filled with discussions, learning, and insights from across the #raredisease landscape. Day 3 concluded with keynotes on 'Real-World Data (RWD) in orphan drug development' and 'Building a Sustainable Pipeline for Gene Therapies'. These sessions highlighted the importance of collaboration, patient-centric outcomes, and regulatory advancements 🧬 𝐆𝐨𝐭 𝟔𝟎 𝐬𝐞𝐜𝐨𝐧𝐝𝐬? Check out the key takeaways here: https://lnkd.in/epkGj8UX 📥 Plus, our full conference report—covering insights from the Access & Pricing and Real-World Evidence tracks, as well as Mariam’s panel on evidence generation—will be available next week. Stay tuned! #WODC2024 #MarketAccess #PatientAccess #Pharma #OrphanDrugs #EUHTA #Healthcare #GeneTherapy

It’s the final day of #WODC2024, and our team are making the most of every moment! ⭐ With a wealth of experience in generating real-world insights from healthcare stakeholders across Europe, Senior Consultant Amrit is looking forward to this morning’s keynote, ‘The Use of Real-World Data in Orphan Drug Development and Access Pathways.’ Stay tuned for his key takeaways in our afternoon update! 📍 Be sure to stop by 𝐬𝐭𝐚𝐧𝐝 𝟔𝟐 to connect with our team and discuss your patient access and pricing challenges before you leave Barcelona. Not attending the conference? Subscribe to our newsletter to catch the highlights from day 3! 📰 https://lnkd.in/exy8iWT6 #WODC2024 #RareDiseases #MarketAccess #PatientAccess #Pharma #OrphanDrugs #EUHTA #Healthcare

What a jam-packed day at Fira de Barcelona! 🎉 Day 2 at the World Orphan Drug Congress Europe 2024 brought compelling insights from expert speakers during two fascinating keynotes, focused on the rare disease integration and patient centricity. 🔑 Key takeaway from the 𝐑𝐚𝐫𝐞 𝐃𝐢𝐬𝐞𝐚𝐬𝐞 𝐀𝐜𝐭𝐢𝐨𝐧 𝐏𝐥𝐚𝐧 𝐤𝐞𝐲𝐧𝐨𝐭𝐞: The panel explored how national and EU-level strategies can align to create real impact in rare disease policies. The focus was on collaboration, learning from countries already implementing action plans, and closing gaps in patient care and drug development. 🔑 Key takeaway from the 𝐏𝐚𝐭𝐢𝐞𝐧𝐭 𝐕𝐨𝐢𝐜𝐞 𝐤𝐞𝐲𝐧𝐨𝐭𝐞: The discussion underscored the increasing importance of patient involvement in shaping policy and clinical trials for rare diseases. While progress has been made, the need to formalise patient engagement and involve them earlier is critical to ensure trials and policies truly reflect patient experiences. 📥 Want the full report? Download it here ➡ https://lnkd.in/e4zQcdic #WODC2024 #RareDiseases #PatientAccess #Healthcare #MarketAccess #Pharma #EUHTA #Patients #OrphanDrugs

🗣️ In just a few minutes, Mariam Bibi will take the stage in Theatre 6 at #WODC, alongside our distinguished guest speakers Dr. Ruth Pulikottil Jacob, Andrew Olaye, Josie Godfrey and Daniel de Vicente. This panel will explore how evidence generation strategies can help improve patient access, shape decision-making, and meet the diverse needs of payers, healthcare providers, and patient organisations. Expect a deep dive into the challenges and opportunities in generating strong evidence that supports HTA submissions and demonstrates value in the complex world of rare disease treatments. 🚀 If you’re at the conference, don’t miss this insightful session! Head to Theatre 6 and join the conversation. Plus, keep an 👀 on LinkedIn later today for our "WODC in 60 seconds" daily recap! 📅 24th October📍 Panel Discussion: "Strategic Evidence Generation: Exploring Multiple Stakeholder Needs" #EvidenceGeneration #PatientAccess #RareDiseases #HTA #HealthcareInnovation #OrphanDrugs #StakeholderEngagement World Orphan Drug Congress Europe

🌍 Day 1 at the World Orphan Drug Congress 2024 kicked off with a strong focus on the EU Joint Clinical Assessment (JCA), one of the most significant healthcare policy shifts in a decade. 𝐊𝐞𝐲 𝐝𝐢𝐬𝐜𝐮𝐬𝐬𝐢𝐨𝐧 𝐩𝐨𝐢𝐧𝐭𝐬: 🔑 The JCA, designed as a “one-stop shop” for regulatory and market access decisions, brings both opportunities and challenges. While it promises to streamline patient access, questions remain around pricing negotiations and national HTA processes 👥 Patient involvement was a hot topic, with many highlighting the gap between expectations and the current regulatory framework. Early scientific advice through Joint Scientific Consultations (JSCs) was flagged as critical for smooth navigation through the JCA process 👥 ⚖️ The path ahead is full of complexities, but with early planning and flexible approaches, companies can prepare for what’s to come Our 𝐃𝐚𝐲 𝟏 𝐒𝐮𝐦𝐦𝐚𝐫𝐲 𝐫𝐞𝐩𝐨𝐫𝐭 brings you all the highlights - https://lnkd.in/gMTER9DB #WODC2024 #EUHTA #PatientAccess #Healthcare #MarketAccess #Pharma #EUHTA #jointclinicalassessment

🌍 Who's in Barcelona for the World Orphan Drug Congress Europe this week? 🙋 Our team has already jumped into the action for Day 1 of #WODC2024! Analysts Tia and Solen, and Associate Director Amy attended this morning's keynote panel, "12 weeks to 2025's EU HTA implementation – are we ready?" 🚀 They'll also be diving into discussions around real-world evidence, access, and pricing throughout the day. ❓ What's your perspective on the industry's readiness for EU HTA? Are you facing market access or pricing challenges in the realm of #rarediseases and #orphandrugs in Europe? 📍 Join the conversation at 𝐬𝐭𝐚𝐧𝐝 𝟔𝟐 with Mariam, Amrit, and Amy to explore your EU HTA or pricing challenges! Not attending the conference? 𝐒𝐮𝐛𝐬𝐜𝐫𝐢𝐛𝐞 to our newsletter to catch the highlights from Day 1! 📰 https://lnkd.in/exy8iWT6 #MarketAccess #PatientAccess #Healthcare #Pharmaceuticals #GlobalConference #WODC2024 *𝑳𝒆𝒇𝒕 𝒕𝒐 𝒓𝒊𝒈𝒉𝒕: Solen Monteil, Amy Boyers, Tia Kwong

💡 At Remap Consulting, we are proud to partner with the North West Biotech Initiative (NWBI) to support the mentorship and development of the next generation in the sciences.    Representing team Remap at this year’s NWBI Consulting Case Competition, we have Associate Director Fatima C. as tonight's Keynote Speaker, and Kavitha Baruah, who has been guiding students through the competition’s workshops! 🙌    The workshops, mentored by Kavitha, are designed to help students navigate real-world challenges and develop essential consulting skills.    Meanwhile, Fatima is eager to share her journey and insights into healthcare consulting during the final event, saying: "𝘐 𝘩𝘢𝘷𝘦 𝘴𝘰 𝘮𝘢𝘯𝘺 𝘨𝘳𝘦𝘢𝘵 𝘮𝘦𝘮𝘰𝘳𝘪𝘦𝘴 𝘰𝘧 𝘣𝘦𝘪𝘯𝘨 𝘱𝘢𝘳𝘵 𝘰𝘧 𝘵𝘩𝘦 𝘕𝘞𝘉𝘐 𝘤𝘰𝘮𝘮𝘪𝘵𝘵𝘦𝘦 𝘢𝘴 𝘢 𝘴𝘵𝘶𝘥𝘦𝘯𝘵. 𝘐𝘵'𝘴 𝘣𝘦𝘦𝘯 𝘢 𝘱𝘭𝘦𝘢𝘴𝘶𝘳𝘦 𝘸𝘢𝘵𝘤𝘩𝘪𝘯𝘨 𝘵𝘩𝘦 𝘴𝘰𝘤𝘪𝘦𝘵𝘺 𝘨𝘳𝘰𝘸 𝘰𝘷𝘦𝘳 𝘵𝘩𝘦 𝘺𝘦𝘢𝘳𝘴, 𝘢𝘯𝘥 𝘐'𝘮 𝘵𝘩𝘳𝘪𝘭𝘭𝘦𝘥 𝘵𝘰 𝘣𝘦 𝘢 𝘫𝘶𝘥𝘨𝘦 𝘢𝘵 𝘵𝘩𝘪𝘴 𝘺𝘦𝘢𝘳’𝘴 𝘤𝘰𝘮𝘱𝘦𝘵𝘪𝘵𝘪𝘰𝘯!"   This competition provides a valuable opportunity for aspiring consultants to connect with industry professionals, gain hands-on experience, and showcase their talents. 💼✨    We are looking forward to an evening of meaningful connections, learning, and inspiration. Best of luck to all involved! 🌟    #ConsultingCareers #NWBI #HealthcareConsulting #Mentorship #MarketAccess #Networking #Healthcare #Graduates